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ABSTRACT
Background. Hyperphosphataemia is an independent risk
factor for accelerated cardiovascular disease in chronic kidney
disease (CKD), although the mechanism for this is poorly
understood. We investigated the effects of sustained exposure
to a high-phosphate environment on endothelial function in
cellular and preclinical models, as well as in human subjects.
Methods. Resistance vessels from rats and humans (± CKD)
were incubated in a normal (1.18 mM) or high (2.5 mM) phos-
phate concentration solution and cells were cultured in normal-
(0.5 mM) or high-phosphate (3 mM) concentration media. A
single-blind crossover study was performed in healthy volun-
teers, receiving phosphate supplements or a phosphate binder
(lanthanum), and endothelial function measured was by ﬂow-
mediated dilatation.
Results. Endothelium-dependent vasodilatation was impaired
when resistance vessels were exposed to high phosphate; this
could be reversed in the presence of a phosphodiesterase-5-
inhibitor. Vessels from patients with CKD relaxed normally
when incubated in normal-phosphate conditions, suggesting
that the detrimental effects of phosphate may be reversible.
Exposure to high-phosphate disrupted the whole nitric oxide
pathway with reduced nitric oxide and cyclic guanosine mono-
phosphate production and total and phospho endothelial nitric
oxide synthase expression. In humans, endothelial function was
reduced by chronic phosphate loading independent of serum
phosphate, but was associated with higher urinary phosphate
excretion and serum ﬁbroblast growth factor 23.
Conclusions. These directly detrimental effects of phosphate,
independent of other factors in the uraemic environment,
may explain the increased cardiovascular risk associated with
phosphate in CKD.
Keywords: cardiovascular risk, chronic kidney disease,
endothelial function, nitric oxide, phosphate
INTRODUCTION
Hyperphosphataemia is an independent risk factor for acceler-
ated cardiovascular disease (CVD) in chronic kidney disease
(CKD) [1–7]. CVD is more prevalent in CKD patients than
in the general population and is the biggest single contributor
to markedly reduced life expectancy, with a predominance of
sudden death and heart failure, rather than coronary artery
disease [8–10]. The relationship between conventional CV
risk factors and CV events in CKD has proved difﬁcult to deﬁne
and focus has turned to non-traditional risk factors and thera-
peutic targets, such as hyperphosphataemia [5, 11–14]. Based
on observational data linking elevated phosphate with adverse
outcomes, most patients with advanced CKD receive phosphate-
lowering treatment with oral phosphate binders, although we
lack speciﬁc evidence on the cardiac and survival beneﬁt of
this therapeutic strategy [4, 6, 15–23]. There is also strong
evidence that ‘normal’ phosphate levels at the upper limit of
the reference range increase the CV risk in other populations,
including recipients of a renal transplant, healthy individuals
or individuals without CKD but with pre-existing CV disease
[12, 14, 22, 24]. One explanation may be that serum phosphate
is a poormeasure of total body phosphate, as phosphate is largely
an intracellular anion. This is reﬂected in CKD, where the CV
risk is increased before phosphate levels rise above the reference
range—phosphate seems to be a continuous risk factor, although© The Author 2016. Published by Oxford University Press on behalf of ERA-
EDTA. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted reuse, distribution, and reproduction in any medium,
provided the original work is properly cited.
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a phosphate level within the reference range is largely ignored in
CKD [15].
Phosphate levels can be easily manipulated. Current means
of modiﬁcation may be suboptimal in terms of risk reduction
and because there is limited information about phosphate’s
mechanism of action as a CV risk factor, it has proved difﬁcult
to determine the best approach to altering phosphate levels
[25]. The established view is that elevated phosphate contri-
butes to vascular calciﬁcation and thus CVD [26–28]. However,
alternative mechanisms include direct effects of phosphate on
endothelial function, and effects mediated by regulators of
phosphate homoeostasis, including ﬁbroblast growth factor
23 (FGF-23), a phosphaturic hormone implicated in cardiac
hypertrophy, another common feature of CKD [4, 28–31]. In
reality it is likely to be a combination of these effects that
contributes to CV risk in CKD. Deﬁning the isolated actions
of elevated phosphate independent of other abnormalities of
the uraemic environment is challenging.
Emerging evidence supports direct effects of phosphate on vas-
cular function. Shuto et al. demonstrated impaired endothelial
dysfunction in healthy males following a single high-phosphate
content meal, consistent with an acute effect of phosphate [32].
In the same study, endothelium-dependent vasodilatation was
impaired in rat aortic rings exposed acutely to high-phosphate
concentration. In a preclinical rat model of adenine-induced
CKD, aortic rings from rats fed a low-phosphate diet for
16 days exhibited signiﬁcantly improved endothelium-dependent
vasodilatation compared with animals fed standard rat chow [28].
In cells in culture, there is evidence of disruption of the nitric oxide
(NO) pathway upon exposure to both a low- and high-phosphate
environment, although the authors attributed this to the concomi-
tant reduction in intracellular calcium [33].
Overall, these elegant studies support direct, acute
effects of phosphate on vascular cells and function but
they do not explore more chronic effects that are relevant
to CKD, nor the mechanisms or potential for new therapeut-
ic approaches.
Endothelial dysfunction is a feature ofCKDandmay contribute
to CV risk, probably via disruption of theNOpathway [32, 34, 35].
We hypothesized that phosphate has direct effects on endothelial
function via dysregulation of theNOpathway and this explains the
association between phosphate and CV risk.We show, for the ﬁrst
time, in translational cell to animal to human studies, the direct
effects of prolonged exposure to elevated phosphate concentration
on vascular and endothelial function, speciﬁcally examining the
isolated actions of elevated phosphate independent of other effects
of the uraemic environment.
MATERIALS AND METHODS
For detailed materials and methods, see Supplementary
Methods online.
Vessel studies
Rat mesenteric vessels were utilized and human resistance
vessels came from subcutaneous abdominal fat, removed
prior to the use of diathermy or the harmonic scalpel, at the
beginning of surgery. Twelve-week-old male Wistar-Kyoto
rats were sacriﬁced in accordance with the Animals Scientiﬁc
Procedures Act 1986. Live kidney donors (LKDs) undergoing
nephrectomy for living kidney donation and patients with
CKD undergoing live donor renal transplant were identiﬁed.
Blood samples were collected the day prior to surgery. All
myography experiments were performed on a four-chamber
wire myograph. Experiments were conducted after storage of
the vessels at 4°C in a normal- (1.18 mM) or high-phosphate
(2.5 mM) concentration solution for 16 h (Supplementary
data, Table S1).
Statistical analysis. All responses are expressed as mean ±
standard error of the mean (SEM) and comparison made
between the areas under the curve (AUC) of groups with
Student’s t test, unless otherwise stated. For comparisons
between maximal vasodilation or contractile responses, an
unpaired Student’s t test (rat vessels) or an ANOVA with
Tukey’s post hoc analysis (human vessels) was used. Themedian
L100 (rat vessels only) and the median vessel lengths were
compared with a Mann–Whitney U test. Statistical analysis
was performed in SPSS v 19 (IBM, Armonk, NY, USA).
Cell culture
Cell media was either of standard phosphate concentration
(0.5 mM) or custom formulated (phosphate concentration
3 mM). Cells were grown in standard phosphate concentration
medium until they reached 90% conﬂuence. At the ﬁrst
passage, they were divided into standard and high-phosphate
concentration cells and grown in the appropriate media from
that point.
Clinical study
This was a single-blind crossover study with healthy volun-
teers without CKD. Volunteers were screened to ensure they
were ‘healthy’ prior to inclusion. Each participant attended
three visits. At visit one, patients were randomized to receive
either 500 mg phosphate or 1000 mg of lanthanum three
times daily for 2 weeks. The participants knew which tablet
they were taking but the investigator did not. After 2 weeks,
patients attended for the second visit. After a further 2-week
washout period, patients received the other drug for 2 weeks,
before attending for the ﬁnal visit. Supplementary data,
Figure S1 illustrates the study visit protocol. At each visit, the
same measures were taken and pill counts were performed to
assess compliance.
Serum and plasma samples were sent to the laboratory
and blood was stored at −80°C for FGF-23, cyclic guanosine
monophosphate (cGMP) and vitamin D analysis. Prior to
each visit, a 24 h urine collection was obtained.
Endothelial function was measured using ﬂow-mediated
dilatation (FMD) and measurements were standardized [36].
All recordings and analyses were performed by one investigator.
Vascular stiffness was measured using the SphygmoCor® Vx
system and standardized [37].
Statistical analysis. Data were assessed for normality. Univari-
ate and multivariate linear regression models were constructed
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with change in FMD from baseline as the measure of outcome.
The crossover nature of the study utilizing the same patients for
each arm was taken into account and randomization order
was included in the model. One-third of the images were ran-
domly selected and reanalysed to test reproducibility and
intra-observer variability.
RESULTS
We exposed cells and vessels to two phosphate concentrations,
normal and high (0.5 and 3 mM in cell lines and 1.18 and
2.5 mM in vessels). For context, 0.5 mM is the standard concen-
tration of phosphate in the conventional cell culture medium
suited to the cells utilized, 0.8–1.4 mM is the normal plasma
range in humans, whilst 2.5–3 mM is at the extreme of the
CKD spectrum.
Effect of phosphate on the function of rat and human
vessels in vitro
Table 1 shows the numbers of rat mesenteric vessels used
and their normalized internal diameter (L100), which was
not signiﬁcantly different between the groups. In phenyleph-
rine (PEP) pre-constricted vessels, the endothelium-dependent
vasodilator carbachol was less effective in high- compared
with normal-phosphate conditions (Figure 1A; maximum
vasodilatation 64 ± 9% versus 95 ± 1%; P < 0.001). When we
assessed basal NO production using the NO synthase inhibitor
L-NAME (LN), we found that in normal-phosphate vessels, LN
shifted the concentration–response curve to PEP signiﬁcantly
to the left compared with contraction in the absence of LN
(Figure 1B). In high-phosphate conditions, no signiﬁcant
shift was observed (EC50 + LN: 4.5 ± 2.1 × 10−6 M versus
EC50-LN: 5.3 ± 2.8 × 10−6 M; data not shown). To assess
endothelium-independent vasodilatation, we used the NO
donor sodium nitroprusside (SNP). Vasodilatation to SNP
was reduced in high- versus normal-phosphate conditions
(Figure 1C; maximal vasodilatation 45 ± 22% versus 73 ± 26;
P = 0.02). Adding zaprinast, a phosphodiesterase (PDE5) in-
hibitor (1 × 10−5 M for 1 h), to increase levels of cGMP reversed
the effects of high phosphate, improving vasodilator responses
to carbachol and SNP (Figure 1D and E).
These data are consistent with impaired endothelium-
dependent and -independent vasodilation and reduced basal
NO production in high-phosphate conditions, effects that are
potentially reversible.
To determine whether these ﬁndings could be translated to
humans, we studied resistance vessels from LKDs and patients
with CKD stage 5 (Table 2). Vessels were obtained at the time of
live donor nephrectomy or at the time of transplantation. Com-
parisons were made between subjects with and without CKD.
The former had higher serum phosphate and FGF-23 levels.
Eighty-nine per cent (n = 8) received a phosphate binder. No
patient was taking drugs that interfere with NO metabolism.
Table 3 details the vessels used.
In LKD vessels, in high-phosphate compared with normal-
phosphate conditions, vasodilatation to carbachol was impaired
(Figure 2A; maximum vasodilatation 42.9 ± 12% versus 79.4 ±
8.2%; P = 0.003). Similarly, high-phosphate LKD vessels vaso-
dilated less well to SNP compared with normal-phosphate ves-
sels (Figure 2B; maximum vasodilatation 59.7 ± 13.8% versus
99.8 ± 20.2%; P = 0.02). Impaired vasodilation with carbachol
was also observed in CKD vessels incubated in high- versus
normal-phosphate conditions (Figure 2C; maximum vasodila-
tation 25.3 ± 11.1% versus 75.7 ± 13.6%; P < 0.001).
Interestingly, there was no signiﬁcant difference in either
AUC or maximal relaxation between the CKD and the LKD
vessels incubated in normal-phosphate conditions, supporting
the notion that the effects of phosphatemay be reversible. There
was no signiﬁcant difference in relaxation to SNP between the
CKD vessels incubated in high- or normal-phosphate condi-
tions (Figure 2D). In LKD with normal renal function, both
Table 1. Comparison of numbers of vessels studied for each drug and the corresponding size of the vessels
Incubated in standard phosphate Incubated in high phosphate P
Phenylephrine
Number 12 10
L100 366.5 (292.7–422.3) 401.6 (226.3–525.4) NS
Carbachol
Number 12 10
L100 366.5 (292.7–422.3) 401.6 (226.3–525.4) NS
L-Name
Number 12 10
L100 366.5 (292.7–422.3) 401.6 (226.3–525.4) NS
SNP
Number 11 9
L100 391.9 (311.2–504.3) 396.9 (267.5–525.3) NS
Carbachol and PDE5I
Number 10 13
L100 387.2 (324.2–412.1) 384.1 (341–411.6) NS
SNP and PDE5I
Number 10 13
L100 387.2 (324.2–412.1) 384.1 (341–411.6) NS
Number is the number of vessels for which a complete concentration response curve was obtained. L100 is the normalized internal diameter of the vessels with comparison by the Mann–
Whitney U test.
PDE5I, phosphodiesterase-5 inhibitor (zaprinast); SNP, sodium nitroprusside; NS, not signiﬁcant.
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endothelium-dependent and -independent vasodilation are im-
paired, consistent with the effects observed in our preclinical
model. In CKD resistance vessels endothelium-dependent
vasodilation was blunted in high-phosphate conditions, but
when incubated ex vivo in a normal-phosphate solution, the re-
laxation response was similar to that of healthy LKD vessels.
Effect of phosphate on the NO pathway
Since the data above, in isolated vessels, suggest a direct and
reversible effect of phosphate on the endothelium mediated by
disruption of both basal and stimulated NO production, we
next explored the NO pathway further by examining the effects
of phosphate in cell lines.
F IGURE 1 : Rat mesenteric vessels incubated in a high-phosphate concentration (2.5 mM) solution have impaired endothelium-dependent and
-independent vasodilatation, an effect that can be reversed when the vessels are co-incubated with a phosphodiesterase-5 inhibitor (PDE5I), za-
prinast. Vessels were incubated for 16 h in either a normal (1.18 mM) or high (2.5 mM) phosphate concentration solution and all responses are
expressed as mean ± SEM. (A and C) Vasodilatation to increasing concentrations of carbachol or SNP, respectively, expressed as a % of maximal
contraction with PEP 1 × 10−5 M. (B) Contraction with PEP in the presence and absence of L-NAME. (D and E) Vasodilatation to increasing
concentrations of carbachol or SNP, respectively, in the presence of zaprinast (PDE5I) expressed as a % of maximal contraction with PEP 1 × 10−5 M.
n = 10–13 vessels (see Table 1).
Table 2. Demographics of the study population
Parameter Live donor CKD P
Age (years) 48.8 ± 10.2 44.6 ± 14.5 NS
Male sex (%) 64 44
Systolic BP 134 ± 16 134 ± 24 NS
BMI 29.5 ± 3.6 25.4 ± 3.4 0.02
Dialysis (%) 0 44
eGFR (mL/min/1.73 m2) 95.8 ± 21 8.0 ± 3.0 <0.001
Phosphate (mmol/L) 1.1 ± 0.1 1.7 ± 0.6 0.003
Adjusted calcium (mmol/L) 2.4 ± 0.1 2.5 ± 0.1 NS
FGF-23 (RU/mL) 45.8 (40.5–51.7) 1644 (1135.7–1750.4) <0.001
On any medication (%) 18 100
Calcium-containing phosphate binder (%) 0 33
Non-calcium-containing phosphate binder (%) 0 67
Alfacalcidol (%) 0 78
Cinacalcet (%) 0 0
Antihypertensive (%) 18 89
BP, blood pressure; BMI, body mass index; NS, not signiﬁcant.
Live donor, vessels from live donor nephrectomy; CKD, vessels from recipients of live kidney transplant. Demographics for the patients whose vessels were used are shown in columns two to
four. Live donor, n = 14 and CKD, n = 14.
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F IGURE 2 : Human resistance vessels from patients with (C) and without (A) CKD incubated in a high-phosphate concentration (2.5 mM)
solution have impaired endothelium-dependent vasodilatation. Endothelium-independent vasodilatation is impaired in vessels from humans
without CKD (B) but preserved in those with CKD (D). Vessels were incubated for 16 h in either a normal (1.18 mM) or high (2.5 mM) phosphate
concentration solution and all responses are expressed as mean ± SEM. (A and C) Vasodilatation to increasing concentrations of carbachol ex-
pressed as a % of contraction with PEP 1 × 10−5 M in vessels from living kidney donors without CKD (A) and from patients with CKD stage 5 (C).
(B and D) Vasodilatation to increasing concentrations of SNP expressed as a % of contraction with PEP 1 × 10−5 M in vessels from living kidney
donors without CKD (B) and from patients with CKD stage 5 (D). n = 9–14 vessels (see Table 3).
Table 3. Comparison of numbers of vessels studied for each patient group
CKD Live donor
Normal High Normal High
Length 4.76 ± 0.36 4.52 ± 0.49 4.59 ± 0.35 4.51 ± 0.44
Diameter 494.3 (339–700) 460.9 (340–792) 534.2 (286–879) 438.4 (297–684)
Phenylephrinea 12 9 13 12
Carbachola 12 9 11 12
SNPa 12 9 13 12
Measurements are in microns.
The number of vessels in which a complete concentration response curve was obtained for each drug and the corresponding size of the vessels are presented. Comparison was made with a
one-way ANOVA.
aThese values represent the number of vessels used (n).
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We measured endothelial nitric oxide synthase (eNOS)
expression and NO production in human umbilical vein endo-
thelial cells (HUVECs), as well as nitrotyrosine expression to
investigate the role of reactive oxygen species (ROS) and free
radicals in the high-phosphate environment. Total and phos-
pho eNOS (normalized to GAPDH) and NO levels (data not
shown) were signiﬁcantly reduced in HUVECs cultured in
high-phosphate conditions (Figure 3A and B). There was
evidence of increased free radical formation in a high-
phosphate environment as there was increased expression of
nitrotyrosine (Figure 3C).
The smooth muscle cell is vital for a contractile response
instigated via an intact NO pathway. In view of the impaired
endothelium-independent vasodilatation to SNP observed in
our resistance vessels, we measured cGMP levels in vascular
smooth muscle cells and the resistance vessels exposed to
normal and high-phosphate environments and protein kinase
G (PKG), a cGMP-dependent kinase implicated in the relax-
ation of smooth muscle.
In rat vascular smooth muscle cells (VSMCs), cultured in
high-phosphate conditions, PKG expression was signiﬁcantly
reduced (Figure 3D). In rat mesenteric vessels, cGMP was
F IGURE 3 : HUVECs express reduced total (A) and phospho (B) eNOS and increased nitrotyrosine (C) when cultured in high-phosphate
concentration medium (3 mM). PKG expression is reduced in rat VSMCs cultured in high- compared with normal-phosphate concentration
medium. **P < 0.05. HUVECs andVSMCs were cultured in 0.5mMor 3mMphosphate concentrationmedium. Ten µg of protein was fractionated
on SDS page gels. Primary antibodies for Total eNOS (1:1000), Phospho eNOS (1:200) (both Cell Signalling Technology), nitrotyrosine (1:500, R &
D Systems), PKG (1:200, Enzo Life Sciences) and protein expression normalized to GAPDH. Densitometry was performed. In (A)–(D), top panels
show representative gel from cells cultured in 0.5 or 3mMphosphate concentrationmedium and bottom panels showGAPDH. The panels were all
taken from a single gel and each band represents one well from separate six-well plates.
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higher in vessels incubated in low- versus high-phosphate con-
ditions (715.6(418–1541) pM/µg versus 330.6 (284.1–500.1)
pM/µg; P = 0.0026; Figure 4A). In a high-phosphate environ-
ment, in support of our hypothesis that there is disruption in
the entire NO pathway from the endothelial cell to the smooth
muscle cell, we demonstrate reduced eNOS and PKG and
increased nitrotyrosine expression, and reduced NO and
cGMP production.
Although these data are consistent with a direct effect of
phosphate, we measured intracellular calcium to exclude an
indirect effect mediated by reduction in intracellular calcium.
In HUVECs, intracellular calcium measurements were not
signiﬁcantly different between cells cultured in high- versus
normal-phosphate conditions (Figure 4B; 749.5 ± 13.9 nM
versus 752 ± 54.2 nM; P = not signiﬁcant); rat VSMCs showed
the same pattern (228.3 ± 22.0 nM versus 278 ± 22.4 nM).
Effects of sustained phosphate loading in healthy human
volunteers
To determinewhether the observations onNO and endothe-
lial function in cellular and preclinical models are of physio-
logical relevance in man, we performed a study of phosphate
loading and phosphate binders (lanthanum) in healthy
subjects, using FMD to assess endothelial function. Healthy
volunteers, rather than CKD patients, were selected initially
to allow study of the sole effects of phosphate, independent of
the uraemic milieu.
We recruited 19 volunteers: 63% (n = 12) were female and
the mean age was 42.2 ± 14.3 years (Table 4). At baseline,
mean estimated glomerular ﬁltration rate (eGFR) was 102 ±
10 mL/min/1.73 m2, serum phosphate level was 1.05 ± 0.18
mmol/L and the fractional excretion of urinary phosphate
(FeP) was 14.3 ± 3.4%. Participants were normoglycaemic,
F IGURE 4 : cGMP concentration is signiﬁcantly reduced in rat vessels incubated for 24 h in a high-phosphate concentration solution (A), whereas
the intracellular calcium level inHUVECs is unchanged in a high-phosphate environment (B). (A) Ratmesenteric resistance vessels were incubated in
a 1.18mM (n = 11) or 2.5mM (n = 11) phosphate concentration solution for 24 h. Results are expressed as cGMPpM/µg protein. Analysis was by the
Mann–WhitneyU test. (B) Cells were plated in glass-bottomed plates and cytosolic loading of FURA-2-AMwas achieved by incubating the cells with
FURA-2-AM. Values are mean ± SEM and are from at least four experiments with the number of cells included indicated by (n).
Table 4. Participant demographics at baseline, following lanthanum and phosphate
Parameter Baseline Post-lanthanum Post-phosphate P-value
Age (years) 42.2 ± 14.3
Male sex 36.8% (n = 7)
BMI 26.0 ± 4.1 26.3 ± 3.9 26.3 ± 3.8 NS
Creatinine (µM) 66.4 ± 6.3 65.8 ± 6.8 65.8 ± 6.6 NS
Systolic BP (mmHg) 123.1 ± 15.8 122.9 ± 10.3 119.8 ± 16.8 NS
Diastolic BP (mmHg) 74.5 ± 10.5 75.2 ± 9.4 74.1 ± 12.1 NS
Adjusted calcium (mmol/L) 2.35 ± 0.07 2.36 ± 0.05 2.34 ± 0.09 NS
Phosphate (mmol/L) 1.05 ± 0.18 1.03 ± 0.18 1.06 ± 0.16 NS
Vitamin D3 (nmol/L) 48.2 ± 23.3 40.3 ± 20.6 45.6 ± 25.8 NS
PTH (pg/mL) 5.9 ± 2.1 5.8 ± 1.4 6.4 ± 2.3 NS
FGF-23 (RU/mL) 49.7 (45.9–69.1) 59.1 (38.2–73.4) 66.6 (50.0–84.9) 0.028
FGF-23% change −1 (−19.8–21.7) 19.6 (3.1–38.9) 0.004
FeP (%) 14.3 ± 3.4 11.4 ± 4.3 28.4 ± 9.2 <0.001
Urinary phosphate (mmol/day) 28.4 ± 14.7 23.2 ± 12.3 54.9 ± 19.2 <0.001
Urinary cGMP (nmol/L) 472.8 (312–645.4) 530.6 (288.2–756.4 501.1 (274.9–674.0) NS
Urinary FGF-23 (RU/mL) 46.1 (26.6–288.2) 139.5 (31.3–360.6) 227.9 (39.4–405.8) NS
FMD post-cuff (%) 8.4 (6.2–11.6) 6.6 (3.4–10.3) 3.4 (2.6–5.3) <0.001
FMD post-cuff % change −23.5 (−59 to â 0.2) −58.1 (−71.9 to â 43.4) <0.001
FMD post-GTN (%) 17.7 (13.4–23.2) 17.2 (12.3–23.7) 16.3 (12.1–17.7) NS
PWV (m/s) 7.4 ± 1.9 7.3 ± 1.7 7.1 ± 1.6 NS
AI@75 12.8 ± 12 12.5 ± 13.1 9.9 ± 12.6 NS
BMI, body mass index; BP, blood pressure; PTH, parathyroid hormone; FeP, fractional excretion of urinary phosphate; FMD, ﬂow-mediated dilatation; PWV, pulse wave velocity; AI@75,
aortic augmentation index corrected to a heart rate of 75 beats per minute; NS, not signiﬁcant. P-value is in comparison with baseline values.
Statistically signiﬁcant differences (P < 0.05) between baseline and subsequentmeasures are indicated in bold. % change refers to the% change in a particular parameter when compared with
the value obtained at baseline.
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with normal mean lipid values. The median FMD was 8.4%
(6.2–11.6%) post-cuff inﬂation and 17.7% (13.4–23.2%)
post-GTN spray.
Table 4 shows the effect of each intervention. Phosphate sup-
plementation was associated with a signiﬁcant reduction in
FMD [Figure 5; 3.4% (2.6–5.3%); P < 0.001]. With lanthanum,
FMD also fell [Figure 5; 6.6% (3.4–10.3%); P = 0.033].
Post-GTN, as expected, there was signiﬁcant increase in vessel
diameter but there was no signiﬁcant effect of phosphate sup-
plementation or binding on GTN-mediated dilatation; ran-
domization order was not a predictor of either FMD or
GTN-mediated dilatation. In univariate analyses, the change
in the serum phosphate level from baseline, change in serum
FGF-23 from baseline and FeP were signiﬁcant predictors of
FMD. In a multiple regression model (Table 5), the inclusion
of serum FGF-23 and urinary FeP was signiﬁcantly associated
with the change in FMD from baseline [F(2,54) = 10.1; P <
0.001; r2 = 0.28]. Inclusion of systolic blood pressure, serum
phosphate, age, sex, urinary FGF-23, urinary calcium or urinary
cGMP levels did not increase the amount of variation of change
in FMD explained by the model. By recoding the three drug
categories (no drug, lanthanum, phosphate), we included
effects of lanthanum and oral phosphate in a multivariate
model with the change in FMD as a % of the baseline visit as
the dependent variable. The change in FeP and that in serum
FGF-23 were included as covariates, resulting in an improved
model [F(4,52) = 18.3; P < 0.001; r2 = 0.59].
Urinary cGMP were measured as a marker of endothelial
function, and correlated inversely with FeP, consistent with
disruption of the NO pathway (r =−0.39; P 0.003). In univari-
ate analysis, serum phosphate, age, male sex and FeP were
associated with urinary cGMP levels. Overall, at the end of
the treatment phases of phosphate supplementation and
lanthanum treatment, there was no signiﬁcant difference in
mean serum phosphate, parathyroid hormone (PTH), vitamin
D, adjusted calcium or magnesium levels compared with base-
line visit values. Serum FGF-23 levels increased signiﬁcantly
following phosphate supplementation and fell, albeit not sig-
niﬁcantly, following lanthanum, compared with baseline.
DISCUSSION
This paper investigates the independent, direct actions of
phosphate in cells, vessels and human subjects, in order to
understand the potential effects of phosphate as a CV risk fac-
tor. The prevailing view has been that elevated serum phosphate
increases CV risk by promoting vascular calciﬁcation, andmore
recently that increased levels of FGF-23 contribute to CV risk
by promoting cardiac hypertrophy. Our data provide strong
support for an additional direct effect of phosphate resulting
in endothelial dysfunction, mediated via disruption of the
NO pathway.
Direct actions of phosphate and the NO pathway
The ex vivo studies demonstrate that sustained exposure to
phosphate, independent of other features of the uraemic envir-
onment, causes impaired endothelium-dependent vasodilata-
tion in resistance vessels. This supports a direct detrimental
effect of phosphate, and this appears to be mediated by NO,
with evidence of reduced basal and stimulated NO production.
Endothelium-independent vasodilation is also impaired in rat
and human LKD vessels exposed to high-phosphate concentra-
tion, suggesting disruption of the whole NO pathway. Adding
zaprinast improved both endothelium-dependent and inde-
pendent vasodilatation in vessels incubated in high-phosphate
conditions. Zaprinast inhibits cGMP breakdown, increasing
cGMP levels, and is beneﬁcial in pulmonary hypertension
where endothelial dysfunction is present [38, 39]. This could
be a potential therapeutic option.
Our cellular models support the concept of disruption to the
NO pathway with reduced basal NO, reduced expression of
phosphorylated and total eNOS and PKG, lower concentrations
of cGMP and increased nitrotyrosine expression. Some of these
effects may be reversible. The ﬁnding that CKD vessels incu-
bated in normal-phosphate conditions relaxed as well as LKD
vessels did, with carbachol is consistent with a degree of adapt-
ability and reversibility of the effects of phosphate in CKD.
Actions of phosphate in the uraemic environment
In CKD vessels, endothelium-dependent relaxation was
impaired, but only with incubation in a high-phosphate envir-
onment. In a normal-phosphate environment, CKD vessels
relax as well as LKD vessels. Unlike the LKD and rat vessels,
endothelium-independent relaxation did not appear to be
impaired in CKD.
These ﬁndings may reﬂect adaptive changes during chronic
exposure to high-phosphate concentration in the uraemic
environment, altering the responses to subsequent changes in
F IGURE 5 : Change in FMD from baseline visit measures, following
intervention with lanthanum and phosphate expressed as a % change
from the baseline visit.
Table 5. Multiple regression model with post-cuff FMD as the outcome
measure
Variable B Conﬁdence interval P-value
Lower bound Upper bound
FeP −1.1 −1.9 −0.2 0.014
Serum FGF-23 −0.5 −0.7 −0.2 0.002
Urinary phosphate and serum FGF-23 are signiﬁcant predictors of post-cuff FMD.
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phosphate. Our results conﬂict with a previous study from our
group in human uraemic resistance vessels that showed
impaired endothelium-dependent and, to a lesser extent, inde-
pendent function in CKD [40]. In the present study, CKD ves-
sels showed endothelial dysfunction, compared with normal
vessels, with sustained exposure to high-phosphate concentra-
tion similar to uraemic levels. In contrast, the study of Morris
et al. used no added phosphate [40]. It is likely that the effects of
extracellular phosphate are mediated via changes in intracellu-
lar phosphate, which will equilibrate with time. Removing ves-
sels from a CKD environment will also ‘wash out’ circulating
factors, which may include asymmetric dimethylarginine and
ROS [41, 42]. Phosphate itself might cause increased ROS,
given that nitrotyrosine (a product of tyrosine nitration
mediated by ROS) was increased in cells cultured in high-
phosphate conditions. The timing of such effects and the time-
scale of their reversibility is unclear and requires further study.
Physiological relevance in humans
In vivo, we have shown similar effects to the in vitro studies:
sustained oral phosphate loading causes endothelial dysfunc-
tion. Serum phosphate is <1% of total body phosphate and
did not change signiﬁcantly during treatment. The serum
FGF-23 level rose by around 20% during phosphate loading
and urinary phosphate excretion by 50% compared with
baseline. This suggests that compliance with study medication
demonstrates phosphate homoeostasis and highlights the lim-
itations of serum phosphate as a measure of total body phos-
phate. In early CKD, serum phosphate is maintained within
the reference range and rises consistently only when eGFR
drops below 30 mL/min/1.73 m2, although in population stud-
ies, serum phosphate—even within the ‘normal’ range—is
linked to CV risk. It may be that serum phosphate is an insensi-
tive, homoeostatically regulated marker of total body phosphate
which, in turn, inﬂuences endothelial function. A more precise
estimate of risk may be derived from serum phosphate, FGF-23
levels and urinary phosphate levels—accounting for phosphate
intake and total body excess. This is supported by our ﬁndings
associating elevated serum FGF-23 and urinary phosphate ex-
cretion with poorer endothelial function. FeP is likely to be a
better indicator of actual phosphate leak per nephron than
standard 24 h urinary phosphate, by accounting for serum
phosphate levels [43]. In the clinical setting, it may be possible
to use a phosphate:creatinine ratio or a spot FeP to provide add-
itional information about phosphate intake and activation of
phosphaturicmechanisms.Whether such detail has any clinical
F IGURE 6 : Possible mechanism of action of phosphate as a cardiovascular risk factor causing both a pro-inﬂammatory state and endothelial
dysfunction. Using evidence presented in this manuscript and previous studies, we propose this as the possible mechanism of action of phosphate
resulting in endothelial dysfunction and a pro-inﬂammatory state. Additionally, we have some evidence of an effect of phosphate on cell growth
(data not yet published).
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beneﬁt would need to be investigated in a clinical trial. Several
small studies have demonstrated an association between
FGF-23 and dietary phosphate intake in healthy volunteers
with increased phosphate intake over a few days resulting in
increased levels of serum FGF-23 [44, 45]. Increased levels of
FGF-23 correlate with increased serum phosphate, urinary
excretion of phosphate and vitamin D levels [44]. Urinary
phosphate excretion alone or in combination with measures
of FGF-23 may be a better surrogate for total body phosphate
than the serum phosphate level.
CKD patients may respond differently to sustained phos-
phate loading and thus results from our clinical study cannot
be extrapolated to the CKD population. Our study was not
powered to assess the direct effects of either phosphate supple-
mentation or lanthanum and so no ﬁrm conclusions about
lanthanum and endothelial function can be drawn. We chose
lanthanum as a non-calcium-containing ‘single tablet’ binder,
without well-described effects on confounding factors, for
example the lipid-lowering properties of sevelamer [18].
Further studies on the direct effects of lanthanum on vascular
function, and comparison of different classes of binder or diet,
are merited.
Naturally, there are limitations of our work. We deliberately
used the extreme ends of the phosphate spectrum (not least
because standard concentration medium contains 0.5 mM
phosphate), but dose response experiments using concentra-
tions of phosphate in between 0.5 mM and 3 mM would be
of value. We acknowledge that our ﬁndings are likely to form
only part of the explanation for the increased CV risk associated
with phosphate and it seems probable that vascular calciﬁcation
and FGF-23 and PTH also play a role. However, to help tease
out the isolated effects of phosphate, we deliberately chose to
study it alone and not look at effects of its key regulators, i.e.
FGF-23 and PTH in vivo and in vitro. Similarly, this is why
we used healthy volunteers for our clinical study.
In conclusion, these studies show that phosphate has directly
detrimental effects on the endothelium and vasculature, effects
that are likely to be mediated by disruption of the whole NO
pathway (Figure 6). Some of the effects may be reversible, either
by manipulation of phosphate or pharmacologically, for
example by inhibiting PDE5 (Figure 6). We have previously
shown direct effects of phosphate on inﬂammation, leading to
a pro-inﬂammatory state [46].
The clinical study presented here shows that the in vitro
effects are of functional relevance and likely to play a role in
the CV risk associated with high-phosphate concentration. It
is our impression that intracellular, rather than extracellular
phosphate is central to the observed effects. Drugs which inhibit
cellular phosphate uptake may offer an alternative strategy to
target adverse effects of hyperphosphataemia in CKD. Future
work should consider the measurement of intracellular
phosphate.
SUPPLEMENTARY DATA
Supplementary data are available online at http://ndt.oxford
journals.org.
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